Vedolizumab is superior to adalimumab for achieving clinical remission in ulcerative colitis, according to the first head to head trial of biologics in the condition. The highly anticipated results of the VARSITY study, a placebo double blinded, randomised trial of the anti-integrin agent vedolizumab (Entyvio) versus anti-TNF adalimumab (Humira) were presented for the first time ...
Vedolizumab shows superiority in first head to head trial of biologics in UC
By Michael Woodhead
13 Mar 2019